Novartis launches ready-to-use formulation of Zometa (zoledronic acid), a bone targeted agent for skeletal complications in advanced cancers and multiple myeloma Novartis launches ready-to-use ...
The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the ...
A brief from this year's San Antonio Breast Cancer Symposium detailing research from the AZURE trial that indicates adding the drug Zometa to chemotherapy before surgery may help to shrink breast ...
A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of ...
The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, new research suggests. When the drug was given along with chemotherapy for three ...
CHICAGO (Reuters) - The Novartis bone-strengthening drug Zometa may enhance the effects of chemotherapy, shrinking breast tumors and helping more women avoid a mastectomy, British researchers said on ...
EAST HANOVER, N.J., Dec. 11 /PRNewswire/ -- New data released today demonstrate that the addition of Zometa® (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces ...
Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cancer THOUSAND OAKS, Calif., Nov. 8, 2010 ...
Novartis has notified healthcare professionals about new precautions for the company's two bisphosphonate drugs, Zometa (zoledronic acid) and Aredia (pamidronate disodium). These drugs are used to ...
Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival ...
MILAN, Italy — Zoledronic acid (Zometa, Novartis) is no better at preventing bone metastasis in high-risk prostate cancer patients than standard treatment, results from the Zometa European Study (ZEUS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback